Clearside Biomedical Inc CLSD Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 18, 2024 (filed on Apr 19, 2024)

Insider Name:

Gibney Anthony S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

93,290

Price:

$1.30
Apr 17, 2024 (filed on Apr 19, 2024)

Insider Name:

Gibney Anthony S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

6,710

Price:

$1.25
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Gibney Anthony S

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

45,000

Price:

--
Mar 20, 2024 (filed on Mar 20, 2024)

Insider Name:

Chong Ngai Hang Victor

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

30,000

Price:

$1.60
Mar 18, 2024 (filed on Mar 18, 2024)

Insider Name:

Chong Ngai Hang Victor

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

450,000

Price:

--
Feb 07, 2024 (filed on Feb 09, 2024)

Insider Name:

Whitmore Bradford T

Ownership Type:

Direct Ownership

Securities:

Warrant

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

444,444

Price:

--
Feb 07, 2024 (filed on Feb 09, 2024)

Insider Name:

Whitmore Bradford T

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

444,444

Price:

$1.35
Jan 19, 2024 (filed on Jan 19, 2024)

Insider Name:

Lasezkay George M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-18,000

Price:

$1.27
Jan 19, 2024 (filed on Jan 19, 2024)

Insider Name:

Deignan Charles A.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-12,900

Price:

$1.28
Jan 18, 2024 (filed on Jan 19, 2024)

Insider Name:

Lasezkay George M

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

439,500

Price:

--

Filings by filing date

Apr 18, 2024 (filed on Apr 19, 2024)

Insider Name:

Gibney Anthony S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

93,290

Price:

$1.30
Apr 17, 2024 (filed on Apr 19, 2024)

Insider Name:

Gibney Anthony S

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

6,710

Price:

$1.25
Apr 15, 2024 (filed on Apr 16, 2024)

Insider Name:

Gibney Anthony S

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

45,000

Price:

--
Mar 20, 2024 (filed on Mar 20, 2024)

Insider Name:

Chong Ngai Hang Victor

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

30,000

Price:

$1.60
Mar 18, 2024 (filed on Mar 18, 2024)

Insider Name:

Chong Ngai Hang Victor

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

450,000

Price:

--
Feb 07, 2024 (filed on Feb 09, 2024)

Insider Name:

Whitmore Bradford T

Ownership Type:

Direct Ownership

Securities:

Warrant

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

444,444

Price:

--
Feb 07, 2024 (filed on Feb 09, 2024)

Insider Name:

Whitmore Bradford T

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

444,444

Price:

$1.35
Jan 18, 2024 (filed on Jan 19, 2024)

Insider Name:

Lasezkay George M

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

439,500

Price:

--
Jan 19, 2024 (filed on Jan 19, 2024)

Insider Name:

Lasezkay George M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-18,000

Price:

$1.27
Jan 18, 2024 (filed on Jan 19, 2024)

Insider Name:

Deignan Charles A.

Ownership Type:

Direct Ownership

Securities:

Employee Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

200,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	900 North Point Parkway, Suite 200 ALPHARETTA GA 30005
Tel:	1-678-4308206
Website:	https://clearsidebio.com
IR:	See website

Key People

George Lasezkay President, Chief Executive Officer, Director	Charles A. Deignan Chief Financial Officer	Victor Chong Chief Medical Officer

Business Overview

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Financial Overview

For the fiscal year ended 31 December 2023, Clearside Biomedical Inc revenues increased from $1.3M to $8.2M. Net loss decreased 1% to $32.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects G/L on early Exting of lease relat debt increase from $669K to $1.7M (income), Stock-based Compensation in R&D decrease of 26% to $1.2M (expense).

Employees:	30 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$71.21M as of Dec 31, 2023
Annual revenue (TTM):	$8.23M as of Dec 31, 2023
EBITDA (TTM):	-$24.78M as of Dec 31, 2023
Net annual income (TTM):	-$32.49M as of Dec 31, 2023
Free cash flow (TTM):	-$19.91M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	74,721,139 as of Mar 5, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization